Cargando…

Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Immunochemotherapy

BACKGROUND: We aimed to investigate the predictive value of a systematic serum inflammation index, pan-immune-inflammatory value (PIV), in pathological complete response (pCR) of patients treated with neoadjuvant immunotherapy to further promote ideal patients’ selection. METHODS: The clinicopatholo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhai, Wen-Yu, Duan, Fang-Fang, Lin, Yao-Bin, Lin, Yong-Bin, Zhao, Ze-Rui, Wang, Jun-Ye, Rao, Bing-Yu, Zheng, Lie, Long, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422963/ https://www.ncbi.nlm.nih.gov/pubmed/37576157 http://dx.doi.org/10.2147/JIR.S418276

Ejemplares similares

Comprehensive (18)F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study
por: Cui, Yingpu, et al.
Publicado: (2022)

A Novel Inflammatory-Related Gene Signature Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma
por: Zhai, Wen-Yu, et al.
Publicado: (2022)

Pathological Responses of the Primary Tumor and Locoregional Lymph Nodes After Neoadjuvant Immunochemotherapy in Esophageal Squamous Cell Cancer
por: Huang, Shu Jie, et al.
Publicado: (2022)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)

Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?
por: Ulas, Ezgi B., et al.
Publicado: (2023)

Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis
por: Zhai, Wen-Yu, et al.
Publicado: (2022)

Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Xu, Lei, et al.
Publicado: (2022)

Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study
por: Fei, Kailun, et al.
Publicado: (2023)

Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression
por: Jia, Wenxiao, et al.
Publicado: (2021)

Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
por: Hong, Zhi-Nuan, et al.
Publicado: (2022)

An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Lung Squamous Carcinoma
por: Zhai, Wen-Yu, et al.
Publicado: (2022)

Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa
por: Gao, Lei, et al.
Publicado: (2022)

Enhancing Prediction for Tumor Pathologic Response to Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Cancer by Dynamic Parameters from Clinical Assessments
por: Song, Xin-Yun, et al.
Publicado: (2023)

Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical–pathological outcomes in non-small cell lung cancer
por: Chen, Jiawei, et al.
Publicado: (2022)

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer
por: Han, Wu, et al.
Publicado: (2023)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Zhao, Ze-Rui, et al.
Publicado: (2021)

Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer
por: Cai, Wenhan, et al.
Publicado: (2022)

(18)F‐FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma
por: Wang, Shuohua, et al.
Publicado: (2023)

Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
por: Li, Kaiyuan, et al.
Publicado: (2023)

The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study
por: Feng, Jifeng, et al.
Publicado: (2022)

Current trends of anticancer immunochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Prognostic Value of Tumor Regression Grading in Patients Treated With Neoadjuvant Chemotherapy Plus Surgery for Gastric Cancer
por: Xie, Jian-Wei, et al.
Publicado: (2021)

Trial Watch: Lenalidomide-based immunochemotherapy
por: Semeraro, Michaela, et al.
Publicado: (2013)

Immunochemotherapy for Richter syndrome: current insights
por: Puła, Bartosz, et al.
Publicado: (2019)

Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
por: Yadagiri, Ganesh, et al.
Publicado: (2023)

Bifidobacterium in anticancer immunochemotherapy: friend or foe?
por: Procaccianti, Giorgia, et al.
Publicado: (2023)

Short-term outcomes of robot-assisted versus video-assisted thoracoscopic surgery for non-small cell lung cancer patients with neoadjuvant immunochemotherapy: a single-center retrospective study
por: Pan, Hanbo, et al.
Publicado: (2023)

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer
por: Iwase, Toshiaki, et al.
Publicado: (2021)

A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Yang, Yalan, et al.
Publicado: (2023)

“Major pathologic response” in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy
por: Deng, Hongsheng, et al.
Publicado: (2023)

An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
por: Chen, Yichao, et al.
Publicado: (2016)

The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis—A Case Series of Three Patients
por: Koch, Agnes, et al.
Publicado: (2022)

Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial)
por: Huang, Yingying, et al.
Publicado: (2023)

Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapy
por: Sun, Taotao, et al.
Publicado: (2022)

Inorganic Nanozyme with Combined Self-Oxygenation/Degradable Capabilities for Sensitized Cancer Immunochemotherapy
por: Wang, Jie, et al.
Publicado: (2019)

A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma
por: Feng, Jifeng, et al.
Publicado: (2023)

Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report
por: Zhang, Shuliang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gsbd2ulhg2ga6o9momcjlo1apo